SARS-CoV-2 mAbs continued to be used after FDA deauthorization
Aug 30, 2022
More than 158,000 doses of bamlanivimab-etesevimab and casirivimab-imdevimab were used after deauthorization on Jan. 24, 2022.
Racial, ethnic disparities seen in mAb treatment for COVID-19
Jan 19, 2022
Monoclonal antibody treatment was used infrequently among all racial, ethnic groups; Hispanics received mAbs less often than non-Hispanics.
Intranasal corticosteroids tied to less severe COVID-19 outcomes
Oct 01, 2021
The findings were seen among individuals regularly using steroid nasal sprays before a COVID-19 diagnosis.
Third mRNA COVID-19 vaccine dose appears to be safe
Apr 15, 2022
There were higher reports of low-severity adverse effects but no change in severe events.
Early mAb treatment beneficial for outpatients with COVID-19
Apr 04, 2023
A reduced risk of hospitalization or death was seen at 28 days; a lower risk was seen for all individual mAb products.
N95 respirators can be reprocessed using vaporized hydrogen peroxide
Jan 12, 2022
All reprocessed N95 respirators met primary end points of function and effectiveness; no change was reported in filtration efficiency.
Bivalent mRNA-1273.214 elicits better response against omicron
Sep 27, 2022
A booster dose of mRNA-1273.214 elicits more neutralizing antibodies against omicron compared with mRNA-1273, the original Moderna vaccine, with no new safety concerns.
FDA authorizes first COVID-19 diagnostic test for home use
By
Joe Jancsurak
Nov 20, 2020
The U.S. Food and Drug Administration this week issued an emergency use authorization for the first COVID-19 at-home diagnostic self-test. The Lucira all-in-one test kit is a molecular (real-time loop...
ACIP: Benefits of mRNA COVID-19 vaccines outweigh risks for ≥12s
Jul 12, 2021
After reviewing evidence, including data on risks for myocarditis, vaccination benefits outweigh risks for all populations.
Provider Relief Fund reporting portal opens
Jul 02, 2021
The federal government’s Provider Relief Fund reporting portal opened Thursday.